Sofinnova Management VIII’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Sofinnova Management VIII’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$24.7M	Hold	481,270	–	–	13.51%	4
2017 Q3	$42.9M	Sell	481,270 -211,858	-31%	-$16.1M	26.16%	1
2017 Q2	$41.4M	Sell	693,128 -6,302	-0.9%	-$352K	23.2%	2
2017 Q1	$37.3M	Sell	699,430 -205,556	-23%	-$12.2M	19.68%	3
2016 Q4	$45.2M	Buy	+904,986	New	+$48.5M	25.41%	2

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sofinnova Management VIII's ONCE Position: Q4 2017 in Review

Sofinnova Management VIII held its Spark Therapeutics, Inc. Common Stock (ONCE) position steady in Q4 2017 at 481,270 shares worth $24.7M. The position accounts for 13.51% of the portfolio, ranked #4.

Sofinnova Management VIII first reported a position in ONCE in Q4 2016 and has held it in 5 quarters since. The position peaked at $45.2M in Q4 2016. 160 funds tracked by Wall St. Rank hold ONCE as of Q4 2017.

Sofinnova Management VIII held 481,270 shares of Spark Therapeutics, Inc. Common Stock worth $24.7M as of Q4 2017.
Sofinnova Management VIII left its Spark Therapeutics, Inc. Common Stock share count unchanged in Q4 2017.
Spark Therapeutics, Inc. Common Stock made up 13.51% of Sofinnova Management VIII's portfolio in Q4 2017, its #4 holding.
Sofinnova Management VIII first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2016 and has held it in 5 quarters since.
Sofinnova Management VIII's Spark Therapeutics, Inc. Common Stock position peaked at $45.2M in Q4 2016.
160 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Sofinnova Management VIII's 13F filing for Q4 2017, filed 14 Feb 2018.